Caribou Biosciences, Inc.
CRBU · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -71% | 148.9% | 44.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 60.7% | 89.8% | 73.7% | 89.7% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,627.9% | -326.4% | -691% | -683.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,491.9% | -296.1% | -717.8% | -697.3% |
| EPS Diluted | -1.65 | -1.38 | -1.64 | -1.11 |
| % Growth | -19.6% | 15.9% | -47.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |